Skip to main content

Market Overview

A Cheaper Option To The EpiPen


Mylan NV (NASDAQ: MYL) has been in the spotlight this week after the company substantially increased its EpiPen prices. This led to criticism from presidential candidate Hillary Clinton and the White House Meanwhile, further controversy emerged on the back of disproportionate executive salary surges.

The EpiPen, a device that dispenses epinephrine in the event of anaphylaxis, accounts for almost half of Mylan's total operating profits. Prices have quintupled since the company launched the product in 2007.

A two-pack of the self-injectable Mylan EpiPen retails for more than $600. However, Mylan’s EpiPen isn't the only epinephrine auto-injector out there.

Related Link: Have You Heard About This Generic EpiPen Maker?

For instance, the authorized generic of Adrenaclick goes for $142 at Wal-Mart Stores, Inc. (NYSE: WMT), using a GoodRx coupon. It should be noted that the form of administering this generic drug is not the same as the one for the EpiPen.

"With EpiPen," KATU 2 explained, "you need to remove a blue safety release, push an orange tip against your outer thigh until the pen clicks, and then wait three seconds until the drug is fully injected."

"With the Epinephrine Auto-Injector, you remove two grey caps, push a red tip against your outer thigh until the needle punctures your skin, and then wait 10 seconds until the drug is fully injected."

Adrenaclick is owned by Impax Laboratories Inc (NASDAQ: IPXL), which rose by more than $2 per share on Wednesday as negative sentiment towards Mylan grew. However, it fell with the rest of the biotech sector by Wednesday afternoon.


Related Articles (IPXL + MYL)

View Comments and Join the Discussion!

Posted-In: Adrenaclick EpiPenBiotech Long Ideas News Health Care Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at